Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? by Rotger, Margalida & Telenti, Amalio
EDITORIAL COMMENTARY
Optimizing efavirenz treatment: CYP2B6 genotyping
or therapeutic drug monitoring?
Margalida Rotger & Amalio Telenti
Received: 27 November 2007 /Accepted: 30 November 2007 /Published online: 11 January 2008
# Springer-Verlag 2007
Cytochrome P450 2B6 (CYP2B6) participates in the
metabolism of important therapeutic drugs such as the
nonnucleoside reverse transcriptase inhibitors efavirenz and
nevirapine, used in the treatment of HIV infection [1, 2].
There is significant interindividual variability in hepatic
expression and catalytic activity of CYP2B6 [3, 4].
Accordingly, the pharmacokinetics of efavirenz is character-
ized by high interindividual variability in plasma levels [5].
Generally, therapeutic drug monitoring is recommended
for drugs with a narrow therapeutic range, whereas pharma-
cogenetics is aimed at personalizing prescription, which in a
perfect world would render therapeutic drug monitoring
unnecessary. Both approaches would possibly lead to dose
reduction (and drug saving) if many individuals are exposed
to supratherapeutic dosing in a given population. These
conditions are partially fulfilled for efavirenz. There is a
certain ground for dose adjustment by using drug levels,
although there is no consensus on the association of
pharmacokinetics and efavirenz neuropsychological toxicity
[6–8]. However, some individuals that present significant
neuropsychological toxicity may benefit from dose reduction
[9, 10]. In contrast, there is a good understanding of genetic
variation of CYP2B6 that allows prediction of the pharma-
cokinetics of efavirenz [11–14]. Thus arises the question as
to whether therapeutic drug monitoring or pharmacogenetic
prediction should be used to optimize efavirenz therapy.
Finally, there would be an interest to use less drug in areas
such as Africa, with the goal being less expenditure and the
possibility of treating more individuals; however, it would be
very difficult to implement therapeutic drug monitoring or
pharmacogenetic testing in this continent.
Despite these considerations, it is in the African popu-
lation that Nyakutira et al. (in this issue) investigate the
usefulness of CYP2B6 genotyping in a population pharma-
cokinetic model that considers gender and the presence of
CYP2B6*6 as covariates. CYP2B6*6 is the most common
diminished-function allele across human populations. The
high allele frequency in blacks (49% in this study), and the
fact that 50% of the participants were found to have
efavirenz plasma levels above the generally recommended
threshold of 4 mg/l, led the authors to propose a priori dose
reduction for genetically defined poor metabolizer indi-
viduals. Nyakutira et al. propose that poor metabolizer
individuals could start efavirenz treatment with a reduced
daily dose of 400 mg with the goal of reducing drug use
and minimizing toxicity [15].
At population level, prediction could be improved if
studies included multiple additional CYP2B6 alleles asso-
ciated with diminished metabolic function (http://www.
cypalleles.ki.se). We have previously shown that variabil-
ity in efavirenz plasma levels were better explained by
including in the analysis other loss-of-function alleles in
addition to CYP2B6*6 [13]. Considering variants such as
the CYP2B6*16, *18, *19, *20, *21, *27, and *28, which
ae relevant in the African population, would help reduce the
76% unexplained interindividual variability in efavirenz
drug levels described by Nyakutira et al [15].
Would genotyping dictate how much drug reduction to
effect? Recently, Gatanaga et al. performed a priori dose
reduction to 400 mg in four efavirenz-naive individuals
homozygous for the CYP2B6 *6/*6 and one individual with
*6/*26. Despite the preemptive dose reduction, only one
individual remained with the 400 mg dose, two individuals
required a further decrease to 200 mg/day, and efavirenz
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was discontinued in two patients (in one because of
intolerance) [9]. These results emphasize that despite the
prediction afforded by CYP2B6 genotyping, drug monitoring
may be needed to assess the outcome of such pharmaco-
genetic intervention.
Should these proof-of-concept studies prompt a pharma-
cogenetic-guided trial for efavirenz? The usefulness of a
pharmacogenetic-guided treatment strategy has been recently
proved by the PREDICT-1 study, where prospective screening
for HLA-B*5701 prior to treatment with abacavir resulted in
a significantly lower incidence of hypersensitivity reactions
(Mallal et al., In 4th International AIDS Conference on HIV
Pathogenesis, Treatment and Prevention; Sydney 2007).
Conducting such trial may be of limited relevance in the
case of efavirenz given the unclear association between drug
levels and neuropsychological toxicity, the frequently time-
limited nature of efavirenz adverse events, and the rarity of
severe toxicity. In addition, if one is to hope for maximal
predictability, the study would need to consider multiple
CYP2B6 alleles and possibly genotyping of the accessory
metabolic pathways of efavirenz (di Iulio et al., In 15th
Conference on Retroviruses and Opportunistic Infections;
Boston 2008).
A formal prospective controlled clinical trial would be,
however, an important step in reconciling pharmacogenetics
and therapeutic drug monitoring, a way to understanding the
determinants of efavirenz toxicity, and a step toward evaluat-
ing the economic value of dose reduction of antiretroviral
agents.
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